[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513369":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":65,"collaborators":25,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":25,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University Hospital Heidelberg","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard treatment plan","ACTIVE_COMPARATOR","Model-based NTCP is calculated after plan approval, however, no further adjustments are to be made to the approved treatment plan",[13],"Other: standard treatment plan, no optimization",{"label":15,"type":16,"description":17,"interventionNames":18},"Optimized treatment plan","EXPERIMENTAL","Allocated to Control Calculation of normal tissue complication probability (NTCP) Model-guided replanning. Replanning is performed with Raysearch Raystation. Optimizations objectives are:\n\n1. the optimization objectives that control the maximum dose in the target volume employ a variable, LETd-dependent model for RBE that allows us to include the RBE-variations predicted by the NTCP model\n2. the periventricular volume, defined as the volume closer than 4 mm to the ventricular wall, is included into the optimization with a constraint on its Equivalent Uniform Dose (EUD) and with the variable RBE model described above. Thereby, the combined effect of the RBE variation and increased sensitivity of the periventricular volume, as predicted by the NTCP model, is included.\n\nThe effectiveness of the re-planning is verified by a second NTCP computation.",[19],"Other: model-guided optimization of treatment plan",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"model-guided optimization of treatment plan","original treatmant plans are optimized based on model-based NTCP",[15],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"standard treatment plan, no optimization","original treatment plans are not optimized",[9],[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Semi Harrabi, MD","CONTACT","+496221 56","8201","semi.harrabi@med.uni-heidelberg.de",{"name":38,"role":33,"phone":34,"phoneExt":35,"email":39},"Adriane Lentz-Hommertgen, Phd","adriane.lentz-hommertgen@med.uni-heidelberg.de",[41],{"facility":42,"status":43,"city":44,"state":25,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Department of Radiotherapy, University of Heidelberg","RECRUITING","Heidelberg","69120","Germany","DE",{"type":49,"coordinates":50},"Point",[51,52],8.69079,49.40768,{"lat":52,"lon":51},[55,60],{"name":56,"role":33,"phone":57,"phoneExt":58,"email":59},"Juergen Debus, Prof. Dr. Dr.","+49 6221 56","8200","juergen.debus@med.uni-heidelberg.de",{"name":61,"role":33,"phone":62,"phoneExt":63,"email":64},"Adriane Hommertgen, Dr. med.","0622156","34091","adriane.hommertgen@med.uni-heidelberg.de",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Juergen Debus","Department Head","100513369","phase-2-feasibility-of-individualized-model-guided-optimization-of-proton-beam-treatment-planning-in-patients-with-low-grade-glioma-100513369",false,"NCT05964569","Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma","Prospective Phase II Trial to Assess Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma Multicentric, Prospective Interventional, Randomized, Observer Blind Two Arm (Active Control), Parallel Group Investigator-initiated Phase II Trial","INDIGO","Inclusion Criteria:\n\n* Age \\> 18 years\n* histologically proven low-grade glioma\n* indication for definitive or adjuvant radiotherapy\n* ability to understand character and personal consequences of the clinical trial\n* written informed consent\n\nExclusion Criteria:\n\n* previous cerebral irradiation\n* contraindication for contrast-enhanced MRI\n* neurofibromatosis\n* participation in another clinical trial with competing objectives","ALL","18 Years",{"count":80,"type":81},120,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Low-grade glioma (LGG) represent typically slowly growing primary brain tumors with world health organization (WHO) grade I or II who affect young adults around their fourth decade. Radiological feature on MRI is a predominantly T2 hyperintense signal, LGG show typically no contrast uptake. Radiotherapy plays an important role in the treatment of LGG. However, not least because of the good prognosis with long term survivorship the timing of radiotherapy has been discussed controversially. In order to avoid long term sequelae such as neurocognitive impairment, malignant transformation or secondary neoplasms initiation was often postponed as long as possible",[87],"Low Grade Glioma","2024-01-04",{"date":90,"type":91},"2024-01-05","ACTUAL",{"date":93,"type":91},"2023-11-11",{"date":95,"type":81},"2028-11-11",{"name":5,"class":6},1]